RUC. Repositorio da Universidade da Coruña
Publication
Artículo científico (JournalArticle)
New Mutations in ADC-Type β-Lactamases From Acinetobacter Spp. Affect Cefoxitin and Ceftazidime Hydrolysis
This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at: https://doi.org/10.1093/JAC/DKU163., [Abstract] Objectives: Two natural variants of ADC-type β-lactamases of Acinetobacter spp., ADC-1 and ADC-5, differ by nine mutations in their protein sequence. ADC-5 hydrolyses cefoxitin better than ADC-1 and the opposite is true for ceftazidime. We produced single and combined mutations in ADC-5 and characterized the variants microbiologically and biochemically to determine which amino acid residues are involved in the hydrolysis of β-lactam antibiotics in this family of β-lactamases.
Methods: Site-directed mutagenesis, with blaADC-5 as a source of DNA, was used to generate nine single mutated and three combined mutated enzymes. The proteins (wild-type and derivatives) were then expressed in isogenic conditions in Escherichia coli. MICs of β-lactams were determined using Etest strips. ADC-1, ADC-5, ADC-5-P167S and ADC-5-P167S/D242G/Q163K/G342R were also purified and the kinetic parameters determined for ceftazidime, cefoxitin, cefalotin and ampicillin.
Results: Single mutations did not significantly convert the hydrolysis spectrum of the ADC-5 enzyme into that of the ADC-1 enzyme, although among all studied mutants only the quadruple mutant (ADC-5-P167S/D242G/Q163K/G342R) displayed microbiological and biochemical properties consistent with those of ADC-1.
Conclusions: Although some single mutations are known to affect cefepime hydrolysis in ADC-type β-lactamases, little is known about ceftazidime and cefoxitin hydrolysis in this family of β-lactamases. Hydrolysis of these antibiotics appears to be positively and negatively affected, respectively, by the Q163K, P167S, D242G and G342R amino acid replacements., This study was funded by grants from the European Community, FP7, ID: 278232 (MagicBullet), and by Plan Nacional de I+D+I 2008–2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), cofinanced by the European Development Regional Fund (EDRF) ‘A Way to Achieve Europe’. It has also been funded by the Fondo de Investigación Sanitaria (grant PI12/00552). F. K. is a research associate of the FRS-FNRS (Brussels, Belgium)
Project:
EC / FP7 278232
,
MINECO RD12-0015-0002
,
MINECO PI12-00552
View at: https://hdl.handle.net/2183/49358